drugset / Trial / NCT06549855
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Not yet recruiting
10 enrolled
Peking University People's Hospital
Beijing Chao Yang Hospital · collabHuazhong University of Science and Technology · collabPeking Union Medical College Hospital · collabPeking University Third Hospital · collabShandong University · collabShengjing Hospital · collabTianjin Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Timeline
- Start
- 2024-10
- Primary completion
- 2029-07
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 320 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | medroxyprogesterone acetate | Other / unclassified | 500 mg | Oral |